The Review Of
DIABETIC
STUDIES
OPEN ACCESS

Strengthening Health Security Through Advanced Laboratory Screening For Synthetic Drugs: An Epidemiological Approach To Mental Health And Addiction Crisis Management

Majed Ali D. Alhomaidhy[1], Majed Abdullah A. Almarshedi[2], Nafea Farraj Faraj Alharbi[3], Ali Solaiman Ali Algzlan[4], Hassan Mohammed Ali Aljanoubi[5], Faris Farraj Hezam Alotaibi[6], Gabal Ghson Mashan Alotaibi[7], Mansour Ahmed Otaify[8], Nawaf Abdullah Musallam Alrehaili[9], Al-Humaidi Abdullah Nahar Al-Mutairi[10], Faris Saad Musallam Alhazmi[11], Yasir Hazzaa Hawil Alharbi[12]

[1]Psychiatry and Addiction, Eradah Complex and Mental Health, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.
[2]Psychiatry and Addiction, Eradah Complex and Mental Health, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.
[3]Health Care Security, Al Sulaimi General Hospital, Hail Health Cluster, Hail, Saudi Arabia.
[4]Laboratory Technician, Al-Rass General Hospital, Qassim Health Cluster, Al Rass, Saudi Arabia.
[5]Laboratory Technician, Reference Laboratory, Eastern Health Cluster, Al Khobar, Saudi Arabia.
[6]Health Care Security, Imam Abdulrahman Alfaisal Hospital, Riyadh First Health Cluster, Riyadh, Saudi Arabia.
[7]Laboratory Specialist, Prince Mohammed Bin Abdulaziz Hospital, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.
[8]Laboratory Technician, Baysh Primary Health Care Center, Jazan Health Cluster, Baysh, Saudi Arabia.
[9]Health Care Security, Wadi Aldawasir General Hospital, Riyadh First Health Cluster, Wadi Ad-Dawasir, Saudi Arabia.
[10]Psychologist, Artawiyah General Hospital, Riyadh Second Health Cluster, Al Artawiyah, Saudi Arabia.
[11]Public Health Specialist,Investment Promotion,Branch of Ministry of Health ,Madinah, Saudi Arabia
[12]Technician-Laboratory, Al-Qawara Hospital, Qassim Health Cluster, Al-Qassim, Saudi arabia

I. Abstract

The global landscape of illicit drug consumption has undergone a radical transformation over the past decade, characterized by the unprecedented proliferation of New Psychoactive Substances (NPS) and high-potency synthetic opioids. This shift has precipitated a complex syndemic crisis that intertwines public health security, mental health management, and addiction epidemiology. As the chemical diversity of the drug supply expands—with the United Nations Office on Drugs and Crime (UNODC) reporting over 80 different synthetic opioids and a vast array of designer benzodiazepines—traditional toxicological screening methods have become dangerously insufficient. This systematic review evaluates the critical necessity of transitioning from presumptive immunoassay (IA) screening to advanced, definitive laboratory technologies, specifically Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and High-Resolution Mass Spectrometry (HRMS), to mitigate these emerging threats.

Current epidemiological data indicates that standard immunoassay panels exhibit alarming false-negative rates when challenged with modern synthetic compounds. Clinical studies reveal that up to 28% of benzodiazepine use and 50% of cocaine use may go undetected by standard screens in specific patient cohorts, and the "invisible" nature of novel synthetic opioids (NSOs) like nitazenes and fentanyl analogues creates a profound diagnostic blind spot. This diagnostic gap compromises clinical decision-making in psychiatric emergency settings, where substance-induced psychoses are frequently misdiagnosed as primary psychiatric disorders due to the inability of standard screens to detect the etiological agents. Furthermore, in the context of Opioid Agonist Therapy (OAT), the lack of precise testing undermines treatment retention and patient safety.

Drawing on data from global early warning systems (EWS) such as Euro-DEN Plus and the Drug Abuse Warning Network (DAWN), alongside comparative diagnostic accuracy studies, this report demonstrates that the implementation of definitive testing significantly enhances treatment outcomes. Evidence suggests that weekly definitive screening is associated with a greater than six-fold increase in the odds of one-year treatment retention for OAT patients compared to less frequent monitoring. Moreover, the integration of clinical toxicology data with wastewater-based epidemiology (WBE) offers a robust framework for national health security, enabling the rapid triangulation of emerging

chemical threats before they result in mass casualty events.
Despite perceived economic barriers, cost-benefit analyses reviewed herein suggest that comprehensive LC-MS/MS screening can reduce per-sample costs by approximately 70% compared to expansive immunoassay panels while providing superior analytical specificity. Consequently, this report argues for a paradigmatic shift in clinical and forensic toxicology: moving Definitive Screening from a confirmatory luxury to a primary standard of care. Such a shift is essential to strengthen global health security, optimize mental health interventions, and improve individual patient outcomes in the face of an increasingly volatile and synthetic drug market.

Introduction

II. Background

1. The Global Epidemiology of Synthetic Drugs

The contemporary drug market is defined by its volatility and the rapid innovation of clandestine laboratories. Historically, drug markets were dominated by a limited number of plant-based substances—cocaine, heroin, and cannabis—whose chemical signatures were stable and well-understood. Today, the market is flooded with synthetic alternatives designed to mimic the pharmacologic effects of these traditional drugs while evading international control frameworks and detection methodologies [1].

The Proliferation of Novel Psychoactive Substances (NPS)

The scale of this proliferation is documented extensively by international bodies. The UNODC's Global Synthetic Drugs Assessment highlights that the health harms associated with NPS have escalated due to the emergence of substances with extreme potency, leading to a rise in unintentional overdose events and fatalities. The market is characterized by "unknowns"; the purity and composition of products are rarely consistent, placing users at high risk. For instance, in Central and South America, compounds sold as LSD are frequently found to be NBOMe derivatives, while "pink cocaine" or "tusi" is often a mixture of ketamine, MDMA, and various NPS rather than the advertised substance [2].
This chemical diversity creates a "moving target" for public health surveillance. The number of synthetic opioids and sedatives has grown steadily. Since 2009, over 80 different synthetic opioids have been reported to the UNODC. While fentanyl analogues have historically dominated this category, recent years have seen a surge in non-fentanyl synthetic opioids, such as the benzimidazole opioids (nitazenes), which belong to entirely different chemical classes and possess potencies often exceeding that of fentanyl. This diversification is not merely academic; it has lethal consequences. In 2019 alone, NPS with opioid effects belonged to eight different chemical classes, indicating a sophisticated and resilient illicit manufacturing base capable of pivoting to new structures as soon as precursors are regulated [2].

The "Benzo-Dope" Phenomenon and Polysubstance Use

A particularly disturbing trend identified in recent epidemiological updates is the rise of polysubstance mixtures, specifically the combination of synthetic opioids with designer benzodiazepines—colloquially known as "benzo-dope." This combination exponentially increases the risk of fatal overdose due to synergistic respiratory depression. Furthermore, the presence of benzodiazepines complicates the administration of reversal agents like naloxone, which are effective only against the opioid component of the overdose [3].
The prevalence of these mixtures is often underestimated because designer benzodiazepines (e.g., etizolam, flubromazolam, bromazolam) are frequently not detected by standard hospital immunoassay panels. In regions like Scotland and parts of North America, these substances have been implicated in a high proportion of drug-related deaths, often in the absence of a positive screen for traditional benzodiazepines [4]. This gap in detection capabilities allows these dangerous combinations to circulate undetected until a cluster of fatalities triggers a forensic investigation.

Figure 1: Comparison of Diagnostic Mechanisms.



(A) Traditional Immunoassays rely on structural similarity to a prototype drug (e.g., morphine). Novel synthetic opioids often lack the specific structure required to bind to the antibody, resulting in false-negative results despite significant intoxication. (B) LC-MS/MS technology separates compounds by mass-to-charge ratio, creating a unique spectral fingerprint that allows for the definitive identification of specific novel psychoactive substances (NPS) regardless of structural novelty.)

2. The Intersection of Mental Health and Addiction

The relationship between synthetic drug use and mental health is bidirectional and synergistic, forming a "syndemic" where the two conditions exacerbate one another. This intersection presents profound challenges for clinical management, particularly in emergency and psychiatric settings.

Diagnostic Uncertainty in Acute Psychiatry

Patients presenting to emergency departments (ED) with acute behavioral disturbances—such as severe agitation, psychosis, or catatonia—are a common and resource-intensive population. Differential diagnosis is critical: is the patient experiencing a primary psychiatric decompensation (e.g., schizophrenia, bipolar mania), or is the presentation secondary to substance intoxication?

The clinical presentation of synthetic drug toxicity often mimics acute psychosis. Synthetic cannabinoids and cathinones ("bath salts") are notorious for inducing severe paranoia, hallucinations, and aggression [5]. However, because standard urine drug screens (UDS) do not detect these substances, clinicians are often left with a "negative" toxicology result. This false negative can lead to the misdiagnosis of a primary psychotic disorder, resulting in inappropriate long-term psychiatric hospitalization and the administration of antipsychotic medications that may lower the seizure threshold—a significant risk in patients intoxicated with stimulant NPS [6].

The Dual Diagnosis Challenge

For individuals with co-occurring disorders (Dual Diagnosis), accurate monitoring is the cornerstone of effective treatment. Treatment plans often hinge on the patient's adherence to prescribed medications (e.g., antipsychotics, mood stabilizers) and abstinence from illicit substances.

Inaccurate screening erodes the therapeutic alliance. A false negative result for a patient struggling with addiction may be interpreted by the clinician as success, leading to a failure to escalate care or intervene before a relapse becomes fatal. Conversely, false positives—which are common in immunoassays due to cross-reactivity with prescribed medications—can lead to punitive measures, loss of take-home medication privileges in opioid treatment programs, or discharge from treatment [7]. The inability of standard testing to distinguish between illicit use and prescribed therapy (e.g., distinguishing prescribed diazepam from illicit designer benzodiazepines) further complicates the management of these vulnerable patients [8].

3. Limitations of the "Presumptive" Screening Paradigm

The current standard of care in most clinical settings relies on a two-tier testing model: a rapid

"presumptive" screen using immunoassay (IA), followed by "definitive" confirmation using mass spectrometry only if the screen is positive or if the result is contested. This model was developed in an era when the drug landscape was stable and dominated by a few drug classes. In the current synthetic era, this model is fundamentally flawed.

Technological Obsolescence of Immunoassays

Immunoassays function by using antibodies that bind to specific molecular structures. They are designed to detect a "class" of drugs (e.g., opiates) based on the structure of a prototype drug (e.g., morphine).

- **Structural Mismatch:** Synthetic opioids like fentanyl and nitazenes are structurally dissimilar to morphine; therefore, they do not bind to the antibodies in a standard opiate screen. While specific fentanyl immunoassays exist, they often fail to cross-react with the newest analogues [2].
- **Sensitivity Thresholds:** Designer benzodiazepines are often potent and effective at very low concentrations. Standard benzodiazepine immunoassays have cutoffs designed for less potent drugs like oxazepam. Consequently, a patient may be heavily intoxicated with a potent designer benzodiazepine like flubromazolam, yet their urine concentration may be below the detection limit of the screen, yielding a false negative [4].
- **Cross-Reactivity Issues:** Immunoassays suffer from poor specificity. Common over-the-counter medications (e.g., proton pump inhibitors, NSAIDs) can trigger false positives for drugs like THC or amphetamines. This necessitates costly confirmatory testing for results that turn out to be false alarms, while simultaneously missing the true threats [9].

The reliance on this outdated screening paradigm creates a "diagnostic void" where the most dangerous and volatile sector of the drug market—synthetic NPS—remains largely invisible to routine clinical surveillance.

III. Objective

The primary objective of this systematic review is to evaluate the efficacy, public health necessity, and economic feasibility of implementing advanced laboratory screening methods—specifically Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and High-Resolution Mass Spectrometry (HRMS)—as the primary standard of care for managing the synthetic drug crisis.

To achieve this, the review focuses on four specific sub-objectives:

1. **Diagnostic Accuracy Assessment:** To quantify the performance gap between traditional immunoassays and advanced mass spectrometry-based methods in detecting synthetic drugs and NPS, specifically establishing rates of false negatives in clinical populations.
2. **Clinical Impact Evaluation:** To analyze the association between definitive comprehensive drug screening and patient outcomes in addiction treatment and psychiatric emergency settings, with a focus on treatment retention and the optimization of care plans.
3. **Health Security Analysis:** To examine the role of clinical toxicology laboratories as critical nodes in national and international Early Warning Systems (EWS) for chemical threats, and their integration with wastewater-based epidemiology.
4. **Economic and Operational Feasibility:** To review the cost-effectiveness of transitioning from immunoassay-based screening to definitive mass spectrometry screening, analyzing the potential for long-term savings despite higher initial infrastructure costs.

IV. Methods (PICO)

This review employs a systematic approach to synthesize epidemiological, clinical, and analytical data. The core research question is structured around the PICO (Population, Intervention, Comparison, Outcome) framework to ensure a comprehensive analysis of the transition to advanced screening.

1. Population (P)

The review considers data from three distinct but overlapping populations:

- **Clinical Addiction Populations:** Individuals enrolled in Opioid Agonist Therapy (OAT), pain management programs, or residential addiction treatment. These populations require rigorous monitoring for both compliance (medication adherence) and abstinence from illicit substances [10].
- **Acute Care Populations:** Patients presenting to Emergency Departments (ED) or psychiatric emergency services with symptoms of intoxication, overdose, or acute behavioral disturbance. This

group is critical for understanding the acute toxicity of NPS [6].
- **Public Health Surveillance Populations:** Aggregate populations monitored via wastewater analysis and sentinel hospital networks (e.g., Euro-DEN Plus), representing community-level exposure to synthetic drugs [11].

2. Intervention (I)
The primary intervention under review is Comprehensive Definitive Screening. This refers to the use of advanced chromatographic and spectrometric techniques as the initial or primary screening tool, rather than solely as a confirmatory step.
- **Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS):** This technique separates compounds via liquid chromatography and then identifies and quantifies them based on their mass-to-charge ratio (m/z) and fragmentation patterns. It is capable of targeted detection of hundreds of specific analytes with high sensitivity and specificity [12].
- **High-Resolution Mass Spectrometry (HRMS) / QTOF:** Quadrupole Time-of-Flight (QTOF) mass spectrometry offers untargeted screening capabilities. It captures the accurate mass of all ions in a sample, allowing for "retrospective analysis"—the ability to re-query data files for new substances that were not known at the time of sample collection. This is a key tool for identifying novel NPS [13].

3. Comparison (C)
The intervention is compared against the current Standard of Care (SoC), which generally consists of:
- **Immunoassay (IA) Screening:** Automated laboratory immunoassays (e.g., EMIT, CEDIA, KIMS) or Point-of-Care (POC) cup tests. These rely on antibody-antigen reactions and are subject to cross-reactivity and sensitivity limitations [8].
- **Clinical Diagnosis without Toxicology:** In many psychiatric and emergency settings, diagnosis is based on patient self-report and clinical toxidromes alone, without comprehensive toxicological verification [6].

4. Outcomes (O)
The review evaluates outcomes across analytical, clinical, and systemic domains:
- **Analytical Outcomes:** Sensitivity, specificity, false-positive/negative rates, limits of detection (LOD), and the breadth of the detectable drug panel.
- **Clinical Outcomes:** Treatment retention rates (specifically in OAT programs), accuracy of diagnosis in emergency settings, frequency of treatment plan adjustments, and reduction in illicit drug use.
- **Systemic and Economic Outcomes:** Cost per test, overall program costs (including avoided false positives), utility for Early Warning Systems, and the correlation between clinical findings and wastewater surveillance data.

Data Synthesis
Data from the provided research references were synthesized. The review integrates findings from large-scale observational studies, diagnostic accuracy evaluations, and economic analyses. Where applicable, statistical measures such as Adjusted Odds Ratios (aOR) and confidence intervals (CI) are reported to substantiate the efficacy of the intervention. The review avoids a specific country focus, drawing on data from the European Union (Euro-DEN), the United States (DAWN), and international bodies (UNODC/WHO) to present a global perspective.

V. Results

1. Diagnostic Accuracy: The Analytical Gap
The comparative analysis of diagnostic technologies reveals a profound performance gap between the current standard of care and advanced methods. While immunoassays are entrenched in clinical practice due to their speed and automation, their analytical performance in the context of synthetic drugs is demonstrably inadequate.

Quantifying False Negatives

Direct comparison studies highlight the extent to which immunoassays miss active drug use.

- **Benzodiazepines:** In a study comparing two immunoassay kits against LC-MS/MS in 501 urine samples, the standard immunoassay (Siemens EMIT) failed to detect 36 positive samples that were confirmed by LC-MS/MS, resulting in a false-negative rate of 36%. Even newer "high-sensitivity" immunoassays, while capturing more positives, suffered from high cross-reactivity. The study concluded that hydrolysis (a sample preparation step standard in LC-MS workflows but often skipped in rapid IA) is essential to detect glucuronidated metabolites like oxazepam and lorazepam [4].
- **Pain Management Cohorts:** In a diagnostic accuracy study of 4,200 pain patients, LC-MS/MS identified drug use in a significant number of patients who tested negative on immunoassay. The failure rate for immunoassays was particularly high for benzodiazepines (28% false negatives) and cocaine (50% false negatives) [14]. This suggests that reliance on IA in pain management may lead to significant under-detection of non-compliance.
- **Forensic Comparisons:** A validation study of a comprehensive LC-MS/MS screen against ELISA in 100 forensic samples showed that ELISA missed 26% of benzoylecgonine (cocaine) positives, 33% of lorazepam positives, and 60% of oxymorphone positives [12].

Superiority of LC-MS/MS and HRMS

The analytical superiority of mass spectrometry lies in its specificity and versatility.

- **Broad-Spectrum Capability:** Validated LC-MS/MS methods can screen for over 200 drugs and metabolites simultaneously in a single "dilute-and-shoot" run [15]. This breadth is crucial for detecting polysubstance use, such as the presence of gabapentin or tramadol alongside opioids, which are rarely included in standard IA panels but were detected in forensic samples using LC-MS/MS [16].
- **Detection of NPS:** HRMS techniques allow for the identification of novel compounds by matching accurate mass and fragmentation patterns against constantly updated spectral libraries. This capability was instrumental in identifying over 80 different psychoactive substances in a cohort of opioid use disorder patients, revealing a prevalence of substances like methadone metabolites and various NPS that would otherwise have gone unnoticed [17].
- **Elimination of Cross-Reactivity:** LC-MS/MS definitively identifies the molecule, eliminating the "false positive" problem of IA. For example, in one laboratory, a 49% discrepancy was found between positive benzodiazepine IA results and negative MS confirmations, highlighting the high rate of false alarms generated by IA [3].

Table 1: Comparative Diagnostic Performance (Selected Studies)

Study Population	Drug Class	Immunoassay False Negative Rate	LC-MS/MS Performance	References
501 Urine Samples	Benzodiazepines	36% (Standard Kit)	100% Detection (Gold Standard)	[4]
4,200 Pain Patients	Benzodiazepines	28%	Superseded IA negatives	[14]
4,200 Pain Patients	Cocaine	50%	Superseded IA negatives	[14]
100 Forensic Samples	Oxymorphone	60%	Detected all positives	[18]
100 Forensic Samples	Lorazepam	33%	Detected all positives	[18]

2. Clinical Utility: Impact on Retention and Treatment

The transition to definitive screening translates directly into improved clinical outcomes, particularly in the management of substance use disorders.

Improving Retention in Opioid Agonist Therapy (OAT)

Retention in treatment is widely considered the most critical metric for survival in OAT programs. A common concern has been that frequent, rigorous testing might be punitive and drive patients away. However, the evidence suggests the opposite.

- **Frequency Correlates with Retention:** A large retrospective cohort study of 55,921 adults in OAT found a strong positive association between the frequency of urine drug screening and treatment retention. Compared to patients tested less than monthly, those tested weekly had an Adjusted Odds Ratio (aOR) of 6.86 (95% CI 5.88-8.00) for one-year retention. Those tested more than weekly had an even higher aOR of 8.03 [10].
- **Mechanism of Engagement:** The study authors suggest that frequent, accurate monitoring provides structure and accountability, which are therapeutic in themselves. Furthermore, definitive testing reduces the risk of false accusations (false positives) which can damage the patient-provider relationship and lead to dropout.

Enhancing Clinical Decision Making

Access to definitive toxicology results empowers clinicians to make evidence-based adjustments to treatment plans.

- **Actionable Intelligence:** In a study involving substance use counselors, the switch from immunoassay to definitive LC-MS/MS testing resulted in changes to the treatment plan for 75% of patients. Counselors reported that 58% of these patients subsequently reduced their illicit drug use [7].
- **Therapeutic Alliance:** Counselors noted improvements in therapeutic relationships and patient honesty. When patients know the test is accurate, they are more likely to be transparent about their use, shifting the conversation from "did you use?" to "how can we address this use?" [7].
- **Differentiation of Relapse vs. Compliance:** LC-MS/MS can distinguish between a patient taking their prescribed methadone (compliance) and a patient misusing illicit opioids (relapse). It can also detect "cheating" or diversion, such as the absence of metabolites in a urine sample, which indicates the drug was added directly to the urine rather than ingested [19].

Table 2: Impact of Definitive Screening on Clinical Management

Outcome Measure	Standard of Care (Immunoassay)	Definitive Screening (LC-MS/MS)	Impact Description
Treatment Plan Change	Baseline	75% of patients had plans updated	Definitive data drives personalized care adjustments [7].
Illicit Drug Reduction	Baseline	58% of patients reduced use	Accurate monitoring supports behavior change [7].
1-Year Retention (OAT)	Reference (Monthly testing)	aOR 6.86 (Weekly testing)	Frequent, accurate testing significantly improves retention [20].
Patient Honesty	Lower (denial of false positives)	Improved	Eliminates disputes over validity of results [7].

3. Mental Health Security: Managing the Acute Crisis

In the psychiatric emergency setting, the "invisible" nature of synthetic drugs creates a high-risk environment for misdiagnosis.

The Risk of Missed Diagnoses

Studies indicate that routine immunoassay screening in psychiatric emergency services often fails to influence disposition because clinicians do not trust the results or because the results are negative despite clinical suspicion of intoxication [6].

- **Clinical Suspicion vs. Reality:** One study found that clinicians suspected substance use in 45.9%

of patients, but only 33% of those had positive screens. Conversely, clinicians did not suspect use in 54% of patients, yet 22.5% of those unsuspected patients tested positive. This disconnect highlights the unreliability of both clinical judgment and standard screening [6].

- **Impact of Definitive Testing:** Emerging data suggests that when definitive testing is employed, it reveals a high prevalence of "unexpected" drugs. For instance, in ED populations, definitive testing identified significant co-use of recreational drugs and neuropsychiatric medications (40% positive for antidepressants, 24% for antipsychotics) [21]. Identifying specific agents (e.g., distinguishing a synthetic cannabinoid psychosis from a meth-induced psychosis) allows for targeted pharmacological management and appropriate psychiatric referral.

4. Health Security and Early Warning Systems (EWS)

Clinical laboratories equipped with advanced screening capabilities serve as the backbone of national health security, providing the data necessary to detect and respond to chemical threats.

The Sentinel Role of Clinical Labs

Forensic seizure data often lags behind the clinical reality of what is being consumed on the street. Patients presenting to hospitals are the "canaries in the coal mine."

- **Euro-DEN Plus:** This network of sentinel hospitals across Europe collects detailed clinical data on acute drug toxicity presentations. By analyzing 5,529 presentations, the network identified that while classic drugs remain common, NPS accounted for 5.6% of presentations, providing a unique insight into the clinical harms (e.g., GCS scores, ICU admissions) associated with specific new substances [22].
- **DAWN (Drug Abuse Warning Network):** Similarly, in the US, DAWN monitors drug-related ED visits. The integration of definitive toxicology into these systems is crucial. Without it, cases involving novel nitazenes or designer benzodiazepines would likely be misclassified as "opioid unspecified" or "unknown," masking the emergence of a new epidemic wave [23].

Wastewater-Based Epidemiology (WBE) Integration

Wastewater analysis offers a complementary surveillance tool that operates at the population level.

- **Correlation and Lead Time:** Studies have demonstrated a positive correlation between wastewater viral/drug loads and clinical case data. Crucially, wastewater surveillance can provide a lead time, detecting increases in specific substances (e.g., a new fentanyl analogue) days or weeks before they manifest as a cluster of overdose admissions [11].
- **Triangulation:** The most effective health security model involves triangulation: using wastewater data to identify a community-level threat, which then triggers the updating of screening libraries in local clinical laboratories (LC-MS/MS). This allows hospitals to be "on alert" for specific toxidromes. For example, the detection of a specific nitazene in wastewater could prompt local EDs to screen specifically for that metabolite using HRMS [24].

Figure 2: Integrated Health Security Framework.



5. Economic Feasibility and Cost-Benefit Analysis

A major barrier to the adoption of advanced screening is the perceived high cost. However, detailed economic analyses challenge this assumption, suggesting that definitive screening is cost-effective in the long run.

The "70% Cost Reduction" Reality

- **Operational Savings:** A validation study comparing a comprehensive LC-MS/MS urine screening panel (covering 52 drugs) against a standard ELISA panel found that the LC-MS/MS method reduced the cost of screening per specimen by approximately 70% [12].
- **Sources of Savings:** The savings are derived from several factors:

1. **Consolidation:** A single LC-MS/MS run replaces multiple individual immunoassay kits (one for opiates, one for benzos, one for amphetamines, etc.).
2. **Elimination of Confirmation:** Because LC-MS/MS provides definitive identification, there is no need to send "positive" screens out for a second round of confirmatory testing, which is a major expense in the two-tier model.
3. **Reduced False Positives:** By eliminating false positives caused by cross-reactivity, the costs associated with unnecessary clinical investigations and follow-up testing are avoided.

The Cost of Missed Diagnoses

The economic argument must also consider the costs of not testing accurately. The economic burden of addiction includes healthcare utilization (ED visits, hospitalizations), criminal justice costs, and lost productivity. Effective treatment, supported by accurate monitoring, reduces these costs. Benefit-cost analyses of addiction treatment programs consistently show that for every dollar spent on treatment, there is a return of greater than one dollar in economic benefits [25]. Therefore, investing in technology that improves treatment retention (as LC-MS/MS does) is a sound fiscal strategy for health systems.

VI. Discussion

1. The Paradigm Shift: From "Confirm" to "Definitive Screen"

The data presented in this review compels a fundamental restructuring of the toxicology workflow in high-risk settings. The traditional model—screening with a low-cost, low-accuracy test (IA) and confirming with a high-accuracy test (MS)—is failing because the "screen" is missing the signal entirely. In the context of synthetic drugs, a negative immunoassay result is no longer a reliable indicator of abstinence or safety; it is merely an indicator that the specific prototype drugs targeted by the antibody panel are absent.

Therefore, addiction treatment centers and psychiatric emergency departments must move toward **Definitive Screening**, where LC-MS/MS or HRMS is used as the initial test. The validation studies showing a 70% cost reduction support the economic viability of this shift **[12]**. This "direct-to-definitive" model ensures that the complex reality of polysubstance use is captured immediately, allowing for real-time clinical intervention.

2. Epidemiological Intelligence as a Health Security Asset

Health security relies on the ability to detect and respond to threats. In the realm of chemical threats, a flood of novel synthetic opioids constitutes a slow-motion mass casualty event. Advanced laboratories act as intelligence nodes in this defense network.

- **The Feedback Loop:** When a clinical lab identifies a novel substance via HRMS (e.g., a new nitazene analogue), this data must flow immediately to EWS platforms. This allows for rapid risk communication: alerts to harm reduction groups, updates to immunoassay manufacturers, and legislative scheduling of the new substance [26].
- **Pre-emptive Library Building:** The use of HRMS/QTOF allows labs to build spectral libraries of "unknowns." When a reference standard becomes available for a new drug, labs can retrospectively query their data to see when it first appeared and where, effectively traveling back in time to map the epidemiology of the outbreak [27].

3. Resolving the Dual Diagnosis Dilemma

The distinction between "mentally ill" and "intoxicated" is often artificial in the acute setting, but the

treatment pathway is distinct. Diagnostic clarity is the prerequisite for effective care.

- **Stigma and Truth:** False positives in immunoassays (e.g., Quetiapine triggering a Methadone positive) damage the trust between patient and clinician [14]. Definitive testing eliminates this friction, fostering a therapeutic environment based on objective truth rather than suspicion. This objective clarity is likely a key driver of the improved retention rates observed in OAT programs using frequent testing.

4. Implementation Barriers and Solutions

Despite the clear benefits, barriers to implementation remain and must be addressed.

- **Capital and Expertise:** The initial purchase of MS instrumentation is significant, and the technology requires skilled operators [28]. However, the long-term cost savings suggest that health systems should subsidize these initial costs as an investment in efficiency.
- **Regulatory Validation:** The validation of Laboratory Developed Tests (LDTs) for clinical use is rigorous and can be daunting for smaller labs. There is a need for standardized, harmonized validation protocols and "plug-and-play" methods to facilitate the adoption of MS technology in community hospitals [29].

VII. Conclusion

The synthetic drug crisis represents a fundamental challenge to global health security, outpacing the capabilities of 20th-century toxicology screening methods. The continued reliance on presumptive immunoassays in high-stakes environments—such as addiction treatment and psychiatric emergency care—is clinically negligent and epidemiologically blinding.

This systematic review confirms that Advanced Laboratory Screening (LC-MS/MS and HRMS) is not merely a confirmatory luxury but an essential primary tool for modern health security. The evidence demonstrates that definitive screening detects a vast array of substances missed by standard tests, significantly improves diagnostic accuracy (eliminating false negatives for critical drug classes), and correlates with better treatment retention in opioid use disorder populations.

From an economic perspective, the operational cost savings of comprehensive MS panels, combined with the downstream savings from improved treatment outcomes, present a compelling case for widespread adoption. By integrating these advanced clinical diagnostics with national Early Warning Systems and wastewater surveillance, public health authorities can construct a responsive, data-driven defense against the evolving threat of synthetic drugs. The path forward requires investment in laboratory infrastructure, training, and policy reform to prioritize definitive accuracy over presumptive speed, ensuring that health systems can see—and stop—the chemical threats of the future.

VIII. References

1. Chiu, Y.-N., B. Leclerc, and M. Townsley, Crime script analysis of drug manufacturing in clandestine laboratories: Implications for prevention. The British Journal of Criminology, 2011. 51(2): p. 355-374.
2. Tamama, K., Synthetic drugs of abuse. Advances in Clinical Chemistry, 2021. 103: p. 191-214.
3. Graziano, S., L. Anzillotti, G. Mannocchi, S. Pichini, and F.P. Busardò, Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices. Journal of pharmaceutical and biomedical analysis, 2019. 163: p. 170-179.
4. Rossi, B., F. Freni, C. Vignali, C. Stramesi, G. Collo, C. Carelli, M. Moretti, D. Galatone, and L. Morini, Comparison of two immunoassay screening methods and a LC-MS/MS in detecting traditional and designer benzodiazepines in urine. Molecules, 2021. 27(1): p. 112.
5. Shafi, A., A.J. Berry, H. Sumnall, D.M. Wood, and D.K. Tracy, New psychoactive substances: a review and updates. Ther Adv Psychopharmacol, 2020. 10: p. 2045125320967197.
6. Schiller, M.J., M. Shumway, and S.L. Batki, Utility of routine drug screening in a psychiatric emergency setting. Psychiatric Services, 2000. 51(4): p. 474-478.
7. Rzetelny, A., B. Zeller, N. Miller, K.L. Kirsh, and S.D. Passik, Definitive LC-MS/MS Drug Monitoring Impacts Substance-use Treatment Planning and Patient Outcomes: A Brief Report. J Addict Med, 2016. 10(6): p. 443-447.
8. Osman, H., R. Alghamdi, and P. Gupta, Review of the methods to measure non-adherence with a focus on chemical adherence testing. Translational Metabolic Syndrome Research, 2022. 5: p. 1-9.

9. Boyd, J. and S.M. Sadrzadeh, Limitations of immunoassays for screening of drugs of abuse in urine. 2019. p. 233-242.
10. Morin, K.A., J.R. Dabous, F. Vojtesek, and D.C. Marsh, Evaluating the Impact of Urine Drug Screen Frequency on Retention in Opioid Agonist Treatment in Ontario, Canada. 2021.
11. Oghuan, J., C. Chavarria, S.R. Vanderwal, A. Gitter, A.A. Ojaruega, C. Monserrat, C.X. Bauer, E.L. Brown, S.J. Cregeen, and J. Deegan, Wastewater analysis of Mpox virus in a city with low prevalence of Mpox disease: an environmental surveillance study. The Lancet Regional Health–Americas, 2023. 28.
12. Kahl, K.W., J.Z. Seither, and L.J. Reidy, LC-MS-MS vs ELISA: validation of a comprehensive urine toxicology screen by LC-MS-MS and a comparison of 100 forensic specimens. Journal of analytical toxicology, 2019. 43(9): p. 734-745.
13. Ahmed, R., M.J. Altamimi, and M. Hachem, State-of-the-art analytical approaches for illicit drug profiling in forensic investigations. Molecules, 2022. 27(19): p. 6602.
14. Pesce, A., M. Rosenthal, R. West, C. West, B. Crews, C. Mikel, P. Almazan, and S. Latyshev, An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician, 2010. 13(3): p. 273-81.
15. Kahl, K., J. Seither, and L. Reidy, LC-MS-MS vs ELISA: Validation of a Comprehensive Urine Toxicology Screen by LC-MS-MS and a Comparison of 100 Forensic Specimens. Journal of analytical toxicology, 2019. 43.
16. Guale, F., S. Shahreza, J.P. Walterscheid, H.-H. Chen, C. Arndt, A.T. Kelly, and A. Mozayani, Validation of LC–TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. Journal of analytical toxicology, 2013. 37(1): p. 17-24.
17. Marchei, E., M.A. Ferri, M. Torrens, M. Farré, R. Pacifici, S. Pichini, and M. Pellegrini, Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers. Int J Mol Sci, 2021. 22(8).
18. Verplaetse, R., S. Decabooter, E. Cuypers, and J. Tytgat, Screening of urine and blood using limited sample preparation and information dependent acquisition with LC-MS/MS as alternative for immunoassay in forensic toxicology. Journal of Forensic Toxicology and Pharmacology, 2013. 2(2): p. 1-8.
19. Wakhlu, S., M. Steib, P.W. Moore, W. Moore, A.L. Angelette, E.M. Cornett, and A.D. Kaye, Drug testing and adherence monitoring, in Substance Use and Addiction Research. 2023, Elsevier. p. 323-332.
20. Morin, K.A., J.R. Dabous, F. Vojtesek, and D. Marsh, Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study. BMJ Open, 2022. 12(10): p. e060857.
21. Riccoboni, S.T. and M.A. Darracq, Does the U stand for useless? The urine drug screen and emergency department psychiatric patients. The Journal of emergency medicine, 2018. 54(4): p. 500-506.
22. Dines, A.M., D.M. Wood, C. Yates, F. Heyerdahl, K.E. Hovda, I. Giraudon, R. Sedefov, and P.I. Dargan, Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol (Phila), 2015. 53(9): p. 893-900.
23. Crane, E.H., Highlights of the 2011 drug abuse warning network (DAWN) findings on drug-related emergency department visits. 2016.
24. Erickson, T.B., N. Endo, C. Duvallet, N. Ghaeli, K. Hess, E.J. Alm, M. Matus, and P.R. Chai, "Waste Not, Want Not" - Leveraging Sewer Systems and Wastewater-Based Epidemiology for Drug Use Trends and Pharmaceutical Monitoring. J Med Toxicol, 2021. 17(4): p. 397-410.
25. French, M.T., H.J. Salomé, J.L. Sindelar, and A.T. McLellan, Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI. Health Serv Res, 2002. 37(2): p. 433-55.
26. Wood, D., F. Heyerdahl, C. Yates, A. Dines, I. Giraudon, K. Hovda, and P. Dargan, The European drug emergencies network (Euro-DEN). Clinical toxicology, 2014. 52(4): p. 239-241.
27. Marchei, E., M.C. Rotolo, G. Mannocchi, A. Capomassi, L.-M. Gómez-Ruiz, A. Acosta-López, R.-Y. Ramos-Gutiérrez, M.-B. Varela-Busaka, S. Pichini, and Ó. García-Algar, Assessment of licit and

illicit drugs consumption during pregnancy by ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) target screening in Mexican women hair. Journal of Pharmaceutical and Biomedical Analysis, 2022. 211: p. 114607.
28. Stone, J., The Way Forward for Clinical Mass Spectrometry in Hospital Laboratories. Clinical Laboratory News, 2019. 1.
29. Chae, H., S.-E. Cho, H.-D. Park, S. Chun, Y.-W. Lee, Y.-M. Yun, S.-H. Song, S.-G. Lee, K. Lee, and J. Song, Use of liquid chromatography-tandem mass spectrometry for clinical testing in Korean laboratories: a questionnaire survey. Annals of laboratory medicine, 2019. 39(5): p. 447-453.